iTeos Therapeutics: Potential Upside from Adenosine Program Amidst TIGIT Challenges
Leerink Partners analyst Daina Graybosch has maintained their bullish stance on ITOS stock, giving a Buy rating on November 12. Daina ...
Business Insider4 天
Corvus Pharmaceuticals’ Soquelitinib: Optimism and Market Potential Drive Buy Rating
Its product pipeline includes Adenosine A2A Receptor Antagonist CPI-444, Adenosine Production Inhibitor Anti-CD73, Adenosine A2B Receptor Antagonist, ITK Inhibitor, and Myeloid Cell Suppression. The ...
manilatimes6 天
iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates
Pro forma cash and investment balance of $683.9 million as of September 30, 2024 expected to provide runway through 2027 across a number of impactful portfolio milestones. WATER ...